Clinical Trials Logo

Filter by:
NCT ID: NCT03843125 Terminated - Clinical trials for Systemic Lupus Erythematosus

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

SLE-BRAVE-X
Start date: September 9, 2019
Phase: Phase 3
Study type: Interventional

The reason for this long term study is to see how safe and effective the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE) who have completed the final treatment visit of study I4V-MC-JAHZ (NCT03616912) or study I4V-MC-JAIA (NCT03616964).

NCT ID: NCT03840902 Terminated - Clinical trials for Non-small Cell Lung Cancer

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Start date: April 16, 2019
Phase: Phase 2
Study type: Interventional

The main purpose of this study was to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.

NCT ID: NCT03836053 Terminated - Clinical trials for Relapsed and/or Refractory Multiple Myeloma

Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma

AMG420
Start date: March 4, 2019
Phase: Phase 1
Study type: Interventional

To confirm the maximum tolerated dose (MTD) from the BI 836909 trial of 400 mcg/d, given as 28-day continuous intravenous infusion in patients with relapsed and/or refractory multiple myeloma, to test the 600 mcg/d dose, given as a 28-day continuous iV infusion.

NCT ID: NCT03834220 Terminated - Solid Tumor Clinical Trials

Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)

Start date: March 22, 2019
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to assess the efficacy of Debio 1347 in terms of objective response rate (ORR) in participants with solid tumors harboring fibroblast growth factor receptor (FGFR)1-3 gene fusion/rearrangement.

NCT ID: NCT03829657 Terminated - Clinical trials for Parkinson's Disease (PD)

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

REDWOOD
Start date: February 22, 2019
Phase: Phase 3
Study type: Interventional

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure

NCT ID: NCT03810313 Terminated - Clinical trials for Central Retinal Vein Occlusion

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

RAVEN
Start date: July 3, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).

NCT ID: NCT03809663 Terminated - Atopic Dermatitis Clinical Trials

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

Start date: March 15, 2019
Phase: Phase 2
Study type: Interventional

This phase 2b study is designed to evaluate the safety and efficacy of tezepelumab as a monotherapy and explore its efficacy as adjunct therapy in subjects with moderate-to-severe atopic dermatitis (AD).

NCT ID: NCT03797261 Terminated - Clinical trials for Acute Myeloid Leukemia

A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

Start date: March 18, 2019
Phase: Phase 1
Study type: Interventional

This dose-escalation study evaluating the safety, pharmacokinetics and preliminary efficacy of venetoclax in combination with AMG 176 in participants with relapsed or refractory acute myeloid leukemia (AML) and participants with Non-Hodgkin's lymphoma (NHL)/diffuse large B-cell lymphoma (DLBCL). This study will include a dose escalation phase to identify the maximum tolerated dose/recommended phase 2 dose (MTD/RPTD) of venetoclax plus AMG 176 as well as a dose expansion phase to confirm safety, explore efficacy, and confirm the suitability of the preliminary RPTD.

NCT ID: NCT03794609 Terminated - Achondroplasia Clinical Trials

Observational Study Investigating Clinical & Anthropometric Characteristics of Children With Achondroplasia.

Start date: June 15, 2018
Phase:
Study type: Observational

This is a registry study in children with achondroplasia, age 0-10 years, to be conducted at multiple clinical centers in several countries. Information collected will include in anthropometric characteristics, related symptoms, tests, & treatments Children's information will be collected in the registry for a maximum of 5 years.

NCT ID: NCT03790865 Terminated - Clinical trials for Prader-Willi Syndrome

Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome

ZEPHYR
Start date: March 25, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

This Phase 2b/3 double-blind, placebo-controlled study will evaluate the safety, tolerability, and effects of livoletide on food-related behaviors in patients with Prader-Willi Syndrome (PWS).